Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.42 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)860.74K
Market Cap
$2.10B
Enterprise Value$1.04B
Total Cash (Recent Filing)$938.94M
Total Debt (Recent Filing)$48.76M
Price to Earnings (P/E)3.3
Beta1.73
Next Earnings
Oct 30, 2025EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding58,101,517
10 Day Avg. Volume600,003
30 Day Avg. Volume860,735
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue25.36
Enterprise Value/Gross Profit29.80
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$51.33Price Target Upside42.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Approval ProcessThe request for a REMS rather than an outright CRL or request for more safety data is a positive sign that the FDA will approve Pyrukynd for thal.
International ApprovalsSaudi FDA approval for Pyrukynd in thalassemia is seen as a positive development.
Market PotentialMitapivat is expected to be tried by up to 50% of transfusion-dependent patients within 5 years, especially as a first step in treatment before gene therapy.
Bears Say
Adverse EventsAGIO shares appear to have been under pressure from three deaths in Pyrukynd patients that newly appeared in the FDA’s FAERS database.
Drug MonitoringIn both of these newly added patients the reporter deems Pyrukynd as most likely to be associated with the event, the stronger of the two endorsement levels available in FAERS.
Safety ConcernsIt is difficult to fully dismiss the impact of the safety concerns on the PDUFA, especially if other non-fatal FAERS entries suggest a risk for liver injury.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $23.41 and its highest was $62.58 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $2.10B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 31, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$1.807 by -$0.123.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.9.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,101,517 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.93 in its last earnings report, missing expectations of -$1.807. Following the earnings report the stock price went down -0.852%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.33 (42.07% Upside)
$51.33 (42.07% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 400.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.26%
12-Months-Change
Fundamentals
Return on Equity
64.05%
Trailing 12-Months
Asset Growth
90.31%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth for PYRUKYND, advancements in regulatory approvals, and strategic partnerships to expand global reach. However, there were also concerns about revenue variability, increased expenses, and challenges in market expansion, which could temper expectations. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$51.33
▲(42.07% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
0.85% Insiders
25.95% Mutual Funds
0.07% Other Institutional Investors
55.82% Public Companies and
Individual Investors